Immune suppressor mechanisms in patients with GI cancer
$90,214ZIAFY2018CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 38205877Paper 38184304Paper 36754451Paper 35366023Paper 35331674Paper 34340996Paper 33508529Paper 33235387Paper 32060001Paper 31996388Paper 31912614Paper 29909986Paper 29427558Paper 29066575Paper 28857485Paper 27816492Paper 24201974Paper 23243621Paper 23108303Paper 23011590Paper 22615204Paper 22304731Paper 21493801Paper 21237299
Abstract
One of the major problems in immune therapy is that we do not understand why some treatments work and others fail in patients. We use samples from patients treated with anti-CTLA4 plus locoregional therapy to better understand how immune based approaches work in HCC. We are studying tumor samples from patients on our studies using gene expression analysis and perform flow cytometry studies on PBMC. These studies are ongoing. So far, we have been able to demonstrate that patients with tumor infiltrating T cells are more likely to respond to anti-CTLA4 plus locoregional therapy. We have recently submitted a manuscript describing correlative studies for NCI-C0120.
View original record on NIH RePORTER →